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An international collaboration was established in 1996 
to monitor the impact of routine Haemophilus infl uenzae 
type b (Hib) vaccination on invasive H. infl uenzae disease; 
14 countries routinely serotype all clinical isolates. Of the 
10,081 invasive H. infl uenzae infections reported during 
1996–2006, 4,466 (44%, incidence 0.28 infections/100,000 
population) were due to noncapsulated H. infl uenzae 
(ncHi); 2,836 (28%, 0.15/100,000), to Hib; and 690 (7%, 
0.036/100,000), to non–b encapsulated H. infl uenzae. In-
vasive ncHi infections occurred in older persons more of-
ten than Hib (median age 58 years vs. 5 years, p<0.0001) 
and were associated with higher case-fatality ratios (12% 
vs. 4%, p<0.0001), particularly in infants (17% vs. 3%, 
p<0.0001). Among non-b encapsulated H. infl uenzae, types 
f (72%) and e (21%) were responsible for almost all cases; 
the overall case-fatality rate was 9%. Thus, the incidence of 
invasive non–type b H. infl uenzae is now higher than that of 
Hib and is associated with higher case fatality.
Haemophilus infl uenzae is differentiated according to its capsular polysaccharide composition into 6 serotypes 
(a–f) and noncapsulated strains (1). Before routine vacci-
nation, H. infl uenzae type b (Hib) caused >80% of inva-
sive H. infl uenzae infections, primarily in healthy children 
<5 years of age (2). In contrast, non–type b H. infl uenzae 
usually causes opportunistic infections (3–7), particularly 
among elderly persons, who often have predisposing medi-
cal conditions such as chronic respiratory disease or immu-
nosuppression (6–11).
The introduction of the Hib conjugate vaccine into na-
tional childhood immunization programs in the 1990s has 
resulted in a marked and sustained reduction in the inci-
dence of invasive Hib disease in many countries (2). How-
ever, concern exists about the long-term effectiveness of the 
Hib immunization programs (12) and possible disease re-
placement by other H. infl uenzae strains (13). Because Hib 
conjugate vaccine reduces pharyngeal carriage (14), other 
H. infl uenzae strains theoretically could take its place and 
cause invasive disease (13,15). Elimination of Hib carriage 
also may reduce natural boosting of immunity, thereby re-
sulting in lower Hib antibody and increased susceptibility 
to invasive Hib disease in the long term (16).
In 1996, a collaborative surveillance network was es-
tablished in Europe to describe the impact of routine Hib 
vaccination on the epidemiology of invasive H. infl uen-
zae disease. By 2006, a total of 28 countries participated 
in surveillance, and 14 countries, comprising an annual 
denominator population of 150 million persons, routinely 
serotyped all invasive clinical H. infl uenzae isolates. We 
describe the epidemiology of invasive H. infl uenzae dis-
ease in countries with established national Hib immuni-
zation programs, devoting particular attention to invasive 
non–type b H. infl uenzae disease.
Methods
A 3-year European Union–funded study (the BIOMED 
II Hib surveillance project) was initiated in 1996 to study 
the epidemiology of invasive H. infl uenzae after the intro-
duction of the Hib conjugate vaccine into national infant im-
munization programs. In 1998, this program was renamed 
European Union Invasive Bacterial Infection Surveillance 
(EU-IBIS) and expanded to include more countries; by 
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2006, a total of 28 countries routinely reported cases to EU-
IBIS (www.euibis.org). Participating countries reported 
cases of invasive H. infl uenzae disease to a central database, 
with basic demographic details, clinical syndrome, out-
come, specimen site, and serotyping data on isolates. The 
UK Health Protection Agency Haemophilus Reference Unit 
(HRU) coordinated development of standardized laboratory 
protocols for growing, serotyping, and PCR genotyping H. 
infl uenzae and exchange of clinical isolates to ensure con-
sistency of results. HRU also provided genotypic confi rma-
tion of serotypes for countries without established reference 
facilities and regularly distributed quality assurance strains 
to participating laboratories to ensure comparability of re-
sults. Annual reports were made available to participants at 
meetings and on the EU-IBIS website. 
Invasive H. infl uenzae disease was defi ned as isolation 
of the organism from a normally sterile site. A case of men-
ingitis was defi ned as H. infl uenzae cultured from cerebro-
spinal fl uid or clinical and/or radiologic features of men-
ingitis with blood culture positive for H. infl uenzae. Other 
clinical presentations, including epiglottitis, pneumonia, 
cellulitis, and osteomyelitis, were defi ned as isolation of H. 
infl uenzae from a normally sterile site (usually blood cul-
tures but occasionally from another sterile site, e.g., joint 
fl uid in septic arthritis or pleural fl uid in empyema) in a 
person with clinical signs and symptoms consistent with 
that presentation. Bacteremia was defi ned as growth of H. 
infl uenzae from blood cultures only, with no distinctive 
clinical syndrome identifi ed.
This study included only countries that routinely vacci-
nated children against Hib before 2000 and serotyped at least 
50% of all clinical isolates. Detailed surveillance methods 
for all participating countries are available at www.euibis.
org. Germany and Israel reported data for children only and 
were included in some of the analyses. Within the United 
Kingdom, data from England and Wales were collected 
separately from Scotland because the surveillance program 
in England and Wales is separate from that in Scotland. 
In Greece, during 1996–2002, surveillance was limited to 
a single prefecture, Attiki, and provided data only for per-
sons <15 years of age; after 2002, national data were avail-
able for Greece. Italy initially relied solely on laboratory 
reporting with voluntary notifi cation of confi rmed cases of 
meningitis, but a more active laboratory-based surveillance 
system was established in 8 Italian regions in 1997–1998 
(Campania, Liguria, Lombardia, Piemonte, Puglia, Toscana, 
Trento, and Veneto), 7 regions in 1999–2002 (Lombardia 
was no longer included), and nationally thereafter. All data 
were collected as part of enhanced national surveillance and 
rendered anonymous at the source.
Data were entered by using Microsoft Excel (Micro-
soft, Redmond, WA, USA), and statistical analysis was 
performed by using Stata 8.0 (www.stata.com). Total and 
age-grouped population estimates used as denominators for 
incidence calculations were obtained either from the nation-
al statistics website of the relevant country or from EU-IBIS 
participants (17). The denominator for disease incidence in 
infants <1 month, 1–5 months, and 6–11 months of age was 
estimated by dividing the number of infants (<1 year of age) 
by 12 and multiplying by the number of months in each age 
group, respectively. For non–type b encapsulated H. infl uen-
zae infections, we combined data on children 5–14 years of 
age with data on adults 15–64 years of age because serotype 
distribution, clinical presentation, and outcomes were simi-
lar for these 2 age groups. To estimate any increase in inci-
dence of non–type b H. infl uenzae disease during the study 
period, an overdispersed Poisson regression model was fi t-
ted for the number of non–type b cases with covariates for 
year and country. To allow for changes in population and 
proportion of total H. infl uenzae isolates serotyped by coun-
try and year, these variables were included in the model as 
offsets. To control for differences in the collection of death 
data, we estimated case-fatality ratios (CFRs) by using the 
number of reported deaths as the numerator and all cases, 
including those for which outcome was not reported, as the 
denominator. We calculated age-adjusted odds ratios (ORs) 
for noncapsulated H. infl uenzae (ncHi) and Hib using lo-
gistic regression; we inclulded age and serotype (e.g., ncHi 
vs. Hib, H. infl uenzae type e [Hie] vs. H. infl uenzae type f 
[Hif]) as independent variables. Ages are given as medians 
and interquartile ranges (IQRs) and compared by using the 
Mann-Whitney U test. Proportions were compared by using 
the χ2 test or Fisher exact test; continuous variables were 
compared by using Student t tests.
Results
During 1996–2006, a total of 14 countries report-
ed 10,081 invasive H. infl uenzae cases, of which 2,836 
(28.1%) were Hib, 690 (7.8%) were other capsulated H. 
infl uenzae, and 4,466 (44.3%) were ncHi. For 125 (1.2%) 
cases, the isolates were identifi ed as non–type b, but com-
plete serotyping was not performed. Capsular serotype was 
not available for 1,964 (19.5%) isolates, mainly because 
the isolate was not available for typing at the reference 
laboratory (e.g., where the isolate could not be recultured). 
The crude overall annual incidence rates for invasive Hib, 
ncHi, and non–type b encapsulated H. infl uenzae infections 
were 0.15, 0.28, and 0.036 cases per 100,000 population 
(Table 1). After adjusting for the proportion of isolates not 
serotyped in each country per year and population changes 
over time, we found a small but statistically signifi cant 
increase in the incidence of non–type b H. infl uenzae dis-
ease (3.6% per year; 95% confi dence interval [CI] 2.1%–
5.2%).
After 2000, when all countries included in the study 
had implemented the Hib vaccine into their national im-
456 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 3, March 2010
H. infl uenzae Disease
munization programs, 7,211 H. infl uenzae cases occurred, 
including 2,005 (27.8%) Hib and 3,172 (44.0%) ncHi 
cases. Patient sex did not differ for Hib and ncHi infec-
tions (931/1,948 [47.8%]) Hib cases in female patients and 
1,519/3,116 [48.7%] ncHi cases in male patients; χ2 = 0.44; 
p = 0.51). However, a higher proportion of women in the 
25–44-year age group developed invasive ncHi infection: 
117/165 (70.9%) for those 25–34 years of age and 93/166 
(56.0%) for those 35–44 years of age, compared with 
1,310/2,785 (47.0%) for the other age groups. Women 25–
44 years of age who had invasive ncHi infection also were 
more likely than men in the same age group to have bac-
teremia (173/288 [60.1%] vs. 69/175 [39.4%]; χ2 = 18.6; 
p<0.001). For Hib, sex was not associated with clinical pre-
sentation for persons in any age group.
Children with Hib disease were much younger than 
those with ncHi (median 4.5 years [IQR 1.5–46.3 years] vs. 
58.2 [IQR 6.8–76.4]) years, p<0.0001) (Figure). More than 
half of Hib cases, compared with fewer than one quarter of 
ncHi cases, occurred in children <5 years of age (χ2 = 438; 
p<0.0001). By contrast, only 13.7% of Hib cases occurred 
in persons >65 years of age, compared with 42.7% of ncHi 
(χ2 = 483; p<0.0001). The most common clinical diagnosis 
was bacteremia for both Hib and ncHi, but the median age 
of persons with Hib bacteremia was much lower than for 
that for those with ncHi bacteremia (Table 2). Hib meningi-
tis occurred mainly in infants, whereas ncHi meningitis oc-
curred in all age groups. Overall, ncHi was responsible for 
one third of all meningitis cases but accounted for 18.4% of 
meningitis cases in children <5 years of age and for 62.9% 
of persons >65 years of age. Hib was responsible for 84.1% 
of epiglottitis cases; only 6.6% were caused by ncHi. Hib 
pneumonia occurred mainly in adults and elderly persons; 
ncHi pneumonia occurred more often in children <5 years 
of age and in elderly persons.
In infants, the overall incidence of Hib and ncHi was 
similar, but incidence of the latter was much higher in the 
fi rst month of life (11.4 vs. 1.2 cases per 100,000 popula-
tion). In the fi rst month, ncHi cases were more likely to 
occur in the fi rst week (148/182 [81.3%]) compared with 
Hib (9/19 [47.4%] cases; χ2 = 11.6; p = 0.001); 112/148 
(75.7%) of ncHi case-patients in the fi rst week of life 
had bacteremia, compared with 50.0% (17/34) of those 
in whom ncHi occurred at 7–30 days of life (χ2 = 8.8; 
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Table 1. Incidence of invasive Hib and non–type b Haemophilus influenzae, by country and year of infection, Europe 1996–2006* 
Incidence (no. cases) 
Country 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 Total
Austria – – – – – – 0 0.04
(3)
0.06
(5)
0.06
(5)
0.07
(6)
0.05
(19)
England, Wales 0.36
(183)
0.40
(205)
0.47
(244)
0.39
(202)
0.48
(248)
0.52
(274)
0.52
(273)
0.57
(302)
0.46
(245)
0.62
(333)
0.65
(350)
0.50
(2859)
Finland 0.29
(15)
0.29
(15)
0.57
(29)
0.35
(18)
0.64
(33)
0.83
(43)
0.23
(12)
0.54
(28)
0.40
(21)
0.73
(38)
0.52
(27)
0.49
(279)
Greece – – – – – – – 0 0.01
(1)
0 0 0.00
(1)
Iceland – – – 1.08
(3)
0 0 0 0 0 0 0 0.13
(3)
Ireland 0.14
(5)
0.30
(11)
0.17
(6)
0.21
(8)
0.08
(3)
0.23
(9)
0.18
(7)
0.20
(8)
0.35
(14)
0.29
(12)
0.52
(22)
0.25
(105)
Italy 0.05
(26)
0.08
(45)
0.04
(23)
0.03
(15)
0.02
(11)
0.02
(10)
0.01
(3)
0.02
(11)
0.01
(4)
0.02
(11)
0.02
(12)
0.03
(171)
Malta – – – 0 0 0 0 0 0.26
(1)
0 0 0.03
(1)
The Netherlands 0.41
(64)
0.44
(68)
0.45
(70)
0.36
(56)
0.38
(61)
0.44
(71)
0.43
(67)
0.64
(103)
0.49
(80)
0.61
(99)
0.61
(99)
0.48
(838)
Norway – – – 1.51
(67)
1.12
(50)
1.04
(47)
1.39
(63)
0.92
(42)
0.83
(38)
0.85
(39)
1.12
(52)
1.10
(398)
Portugal – – – 0.05
(5)
0.07
(7)
0.15
(15)
0.12
(12)
0.09
(9)
0.08
(8)
0.10
(11)
0.16
(17)
0.10
(84)
Scotland – – – 0 0.04
(2)
0.10
(5)
0.34
(17)
0.55
(28)
0.61
(31)
0.65
(33)
0.57
(29)
0.36
(145)
Slovenia – – – – 0.30
(6)
0.80
(16)
0.35
(7)
0.60
(12)
0.60
(12)
0.40
(8)
0.60
(12)
0.52
(73)
Total non–type b H.
influenzae incidence
0.22
(293)
0.26
(344)
0.28
(372)
0.24
(374)
0.27
(421)
0.31
(490)
0.28
(461)
0.31
(546)
0.26
(460)
0.33
(589)
0.35
(626)
0.28
(4,976)
Hib incidence – – – – 0.12
(182)
0.14
(212)
0.23
(376)
0.21
(380)
0.15
(268)
0.13
(239)
0.09
(168)
0.15
(1,825)
Population, millions 132.5 132.8 132.9 153.9 156.3 156.9 165.6 177.4 178.5 179.8 180.6
*Per 100,000 population. Data for Attiki, Greece (1996–2002); Germany; and Israel were not included because their surveillance was limited to pediatric 
cases. Hib, H. influenza type b. 
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p = 0.003). Infections from ncHi in infants decreased after 
the fi rst month of life and remained fairly constant during 
the fi rst year (Figure).
A total of 585 (8.1%) of the 7,211 persons with H. in-
fl uenzae died; CFRs were highest for persons >65 years of 
age and for infants. We found no association between death 
and sex or year of infection. In most age groups, CFRs were 
higher for ncHi than for Hib; the largest difference was for 
infants (Table 3). For both Hib and ncHi, the CFR was low-
er for meningitis than for other clinical presentations. The 
age-adjusted OR for death from ncHi compared with Hib 
was 2.4 (95% CI 1.9–3.1, p<0.0001) overall, 3.3 (95% CI 
1.5–7.5; p = 0.004) for pneumonia, and 3.3 (95% CI 1.5–
7.5; p = 0.004) for bacteremia. The OR for meningitis was 
not signifi cant (OR 0.85, 95% CI 0.4–1.9 years; p = 0.68).
Invasive infections caused by non–type b encapsulated 
H. infl uenzae were rare. Cases did not cluster by country or 
time, and individual serotypes or incidence, either overall 
or in any single country, did not increase during the 11-year 
study period. Of the 690 cases, Hif was the most preva-
lent subtype (500 [72.5%] patients) followed by Hie (143 
[20.7%]) (Table 4). The overall CFR was 9.1% (63/690 
patients). The CFR increased with age and was highest 
for bacteremia (36/292 [12.3%]) and pneumonia (15/127 
[11.8%]) compared with meningitis (5/120 [4.2%]) and epi-
glottitis (0/10). CFR was highest for Hie infections (23/143 
patients [16.1%]), particularly for persons >65 years of age 
(17/72 [23.6%]); however, none of the 22 children <16 
years of age who had Hie infection died. Compared with 
Hif, the age-adjusted OR for death from Hie was 2.0 (95% 
CI 1.1–3.9; p = 0.035). All 3 Hia-related fatalities occurred 
in children <2 years who had meningitis.
The epidemiology of non–type b encapsulated H. 
infl uenzae varied with age. A total of 140 (20.4% of all 
infections) occurred in children <5 years of age. In this 
age group, meningitis (61 [43.6%] patients) was the most 
common clinical presentation and was caused by Hif (49 
patients [80.3%]), Hie (7 patients [11.5%]), and Hia (5 pa-
tients [8.2%]). Children <5 years of age were more likely 
to have meningitis than were older children and adults 
(61/120 [50.8%] vs. 59/548 [10.8%]; χ2 = 83; p<0.0001). 
Two thirds of Hia infections (17/26 [65.4%] patients) oc-
curred in children <5 years of age, compared with 21.2% 
(106/500) of Hif, 9.8% (14/143) of Hie, and 33.3% of Hic 
(3/9). Persons in this age group with either Hif (49/106 
[46.2%] vs. 37/392 [9.4%]; χ2 = 79.0; p<0.0001) or Hie 
(7/14 [50.0%] vs. 15/129 [11.6%]; χ2 = 14.3; p<0.0001) in-
fections were more likely to have meningitis, whereas older 
children and adults were more likely to have bacteremia 
and pneumonia. The CFR for children <5 years of age was 
lower than that for older children and adults (6/140 [4.3%] 
vs. 57/548 [10.4%]; χ2 = 5.0; p = 0.025).
Non–type b encapsulated H. infl uenzae infections 
among the 247 persons 5–64 years of age resulted mainly 
from Hif (17 [69.2%]) and Hie (57 [23.1%]). Most Hic (5/9 
[55.6%]) and Hid (10/12 [83.3%]) infections also occurred 
in this age group. All serotypes were responsible for the 45 
meningitis cases: Hif (26 [57.8%]), Hie (12 [26.7%]), Hid 
(4 [8.9%]), Hic (2 [4.4%]), and Hia (1 case [2.2%]). The 
CFR for this age group was 7.3% (18/247 patients), but no 
persons with meningitis died, compared with 12.0% (9/75 
patients) and 11.5% (6/52 patients) of those with bacter-
emia and pneumonia, respectively.
Almost half the cases (301 [43.6%]) occurred among 
persons >65 years of age; Hif (221/301 [73.4%]) and Hie 
(72/301 [23.9%]) accounted for almost all cases. The over-
all CFR was highest for this age group (39/301 [13.0%] 
patients) and similar for those with bacteremia (17/102 
[16.7%]), pneumonia (9/59 [15.3%]), or meningitis (2/14 
[14.3%]). The CFR for Hie was 23.6% (17/72 patients), 
compared with 10.0% (22/221) for Hif (χ2 = 8.8; p = 0.003) 
for persons >65 years of age.
Discussion
The marked reduction in invasive Hib disease after the 
introduction of the Hib conjugate vaccine had prompted 
concerns that other H. infl uenzae serotypes, ncHi, or other 
respiratory pathogens might fi ll the ecologic niche. How-
ever, little evidence exists for a substantial or sustained 
increase in invasive non–type b H. infl uenzae infections 
(18). The rise in Hib incidence during 2000–2002 resulted 
458 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 3, March 2010
Figure. Age-specifi c incidence for disease caused by Haemophilus 
infl uenzae type b (Hib) and noncapsulated H. infl uenzae (ncHi) for 
all countries combined, Europe, 2000–2006. A) All age groups; B) 
infants <1 year of age.
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mainly from an increase in the United Kingdom and the 
Netherlands; however, rates remained well below those in 
the prevaccine era (19,20).
Although prospective enhanced national surveillance 
may be incomplete (21), comparisons over time and across 
serotypes are largely valid, assuming serotyping is accurate 
and complete. In addition, although lower ascertainment 
might lead to lower estimation of the true incidence of inva-
sive H. infl uenzae disease, it is less likely to affect the clini-
cal presentation, age distribution, outcome, or proportion of 
cases due to the different serotypes. All participating coun-
tries had reference laboratories that routinely serotyped all 
invasive H. infl uenzae strains and participated in an external 
quality assurance scheme. As a result, 80.5% of 10,081 H. 
infl uenzae isolates identifi ed were serotyped. The robustness 
of the surveillance is demonstrated by the incidence of inva-
sive non–type b disease, which remained relatively constant 
over the 11-year study period despite increasing numbers of 
participating countries and provides further confi dence that 
replacement disease is not occurring (18,22,23).
In countries with established Hib immunization pro-
grams, the incidence of ncHi is now higher than that of 
Hib. Unlike Hib, however, invasive ncHi infections occur 
mainly in neonates and elderly persons. Neonatal ncHi in-
fections are well described but account for <5% of all neo-
natal invasive bacterial infections (3,24,25). The infection 
develops rapidly (usually within 48 hours after birth) and 
follows a fulminant course with a high CFR, particularly in 
preterm infants (3). Invasive ncHi disease in neonates also 
is associated with septicemia in the mother, increased com-
plications during labor, and preterm delivery (24,26,27). 
In our study, ncHi was more common among women in 
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Table 2. Hib and ncHi cases, by diagnosis and age group, Europe 1996–2006* 
Age group 
Diagnosis <1 mo 1–5 mo 6–11 mo <1 y 1–4 y 5–14 y 15–44 y 45–64 y >65 y NR Total
Median
age, y 
Hib 
 Meningitis 6  
(31.6)
93
(60.4)
98
(57.6)
197
(57.4)
282
(41.2)
45
(23.0)
26
(10.0)
17
(7.1)
12
(4.4)
1
(12.5)
580
(28.9)
1.6
 Epiglottitis 0 1  
(0.6)
4
(2.4)
5
(1.5)
110
(16.1)
29
(14.8)
45
(17.4)
37
(15.4)
22
(8.0)
0 248
(12.4)
6.7
 Cellulitis 0 7  
(4.5)
18
(10.6)
25
(7.3)
15
(2.2)
3
(1.5)
0 1  
(0.4)
4
(1.5)
0 48  
(2.4)
1.0
 OM/SA 0 4  
(2.6)
5
(2.9)
9
(2.6)
24
(3.5)
4
(2.0)
4
(1.5)
6
(2.5)
1
(0.4)
0 48  
(2.4)
2.1
 Pneumonia 0 3  
(1.9)
5
(2.9)
8
(2.3)
20
(2.9)
15
(7.7)
35
(13.5)
36
(14.9)
47
(17.2)
1
(12.5)
162
(8.1)
46.7
 Bacteremia 11
(57.9)
33
(21.4)
30
(17.6)
74
(21.6)
193
(28.2)
73
(37.2)
102
(39.4)
96
(39.8)
134
(48.9)
2
(25.0)
674
(33.6)
13.6
 Other 0 1  
(0.6)
2
(1.2)
3
(0.9)
10
(1.5)
6
(3.1)
10
(3.9)
11
(4.6)
7
(2.6)
0 47  
(2.3)
34.6
 NR 2  
(10.5)
12
(7.8)
8
(4.7)
22
(6.4)
30
(4.4)
21
(10.7)
37
(14.3)
37
(15.4)
47
(17.2)
4
(50.0)
198
(9.9)
39.0
 All cases 19
(100.0)
154
(100.0)
170
(100.0)
343
(100.0)
684
(100.0)
196
(100.0)
259
(100.0)
241
(100.0)
274
(100.0)
8
(100.0)
2005
(100.0)
4.5
ncHi 
 Meningitis 8  
(4.4)
15
(13.6)
19
(19.4)
42
(10.8)
76
(22.6)
37
(24.2)
65
(14.3)
63
(13.6)
45
(3.3)
4
(20.0)
332
(10.5)
19.7
 Epiglottitis 2  
(1.1)
0 0 2  
(0.5)
2
(0.6)
1
(0.7)
5
(1.1)
5
(1.1)
3
(0.2)
0 18  
(0.6)
42.1
 Cellulitis 0 0 1  
(1.0)
1
(0.3)
4
(1.2)
5
(3.3)
0 0 4  
(0.3)
0 14  
(0.4)
11.6
 OM/SA 0 0 0 0 2  
(0.6)
1
(0.7)
2
(0.4)
2
(0.4)
4
(0.3)
0 11  
(0.3)
56.6
 Pneumonia 10  
(5.5)
14
(12.7)
11
(11.2)
35
(9.0)
39
(11.6)
11
(7.2)
34
(7.5)
56
(12.1)
226
(16.7)
0 401
(12.6)
70.0
 Bacteremia 129
(70.9)
53
(48.2)
46
(46.9)
228
(58.5)
151
(44.8)
74
(48.4)
236
(52.0)
218
(47.0)
759
(56.1)
10
(50.0)
1,676
(52.8)
59.6
 Other 3  
(1.6)
8
(7.3)
8
(8.2)
19
(4.9)
21
(6.2)
5
(3.3)
20
(4.4)
9
(1.9)
38
(2.8)
2
(10.0)
114
(3.6)
31.2
 NR 30
(16.5)
20
(18.2)
13
(13.3)
63
(16.2)
42
(12.5)
19
(12.4)
92
(20.3)
111
(23.9)
275
(20.3)
4
(20.0)
606
(19.1)
61.3
 All cases 182
(100.0)
110
(100.0)
98
(100.0)
390
(100.0)
337
(100.0)
153
(100.0)
454
(100.0)
464
(100.0)
1354
(100.0)
20
(100.0)
3,172
(100.0)
58.2
*Pediatric cases only for Attiki, Greece (1996–2002); Germany (1998 onward); and Israel (1996 onward). Values are no. (%) cases except as indicated. 
Hib, Haemophilus influenzae type b; ncHi, noncapsulated H. influenzae; NR, not recorded; OM/SA, osteomyelitis/septic arthritis. 
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the 25–44-year age group, suggesting that childbearing-
aged women may be at increased risk for invasive ncHi 
infections. This fi nding may refl ect increased exposure, 
for example, because of contact with children or increased 
susceptibility, such as in pregnancy. In older children and 
adults who develop invasive ncHi infections, studies have 
reported that more than half the case-patients had serious 
predisposing medical conditions, such as chronic respira-
tory disease and impaired immunity (3–7). Unfortunately, 
because clinical information collected for individual cases 
in our study was limited, we could not further elucidate 
possible risk factors for invasive infections caused by the 
different serotypes.
Infection from non–type b encapsulated H. infl uenzae 
is extremely rare and mostly caused by Hif and Hie. Other 
population-based studies also have reported a predomi-
nance of Hif and, to a lesser extent, Hie among non–type b 
encapsulated H. infl uenzae in adults and children (3,6,28). 
The clinical presentations of both Hif and Hie disease are 
almost identical and similar to that of ncHi infections in 
that almost half the cases occurred among persons >65 
years of age who usually had bacteremia and pneumonia 
(6,7). Although 44% of Hif infections occurred among per-
sons >65 years of age, compared with 21% among children 
<5 years, the incidence was almost the same in the 2 age 
groups. Hif and Hie have considerably restricted genetic 
diversity, and most infections are caused by a few strains 
that may be intrinsically more pathogenic than noninvasive 
strains (29). Other studies have reported that, as with ncHi, 
60%–80% of persons with invasive Hif disease and Hie had 
underlying conditions that predisposed them to opportunis-
tic infections (3,6,9–11,25,30–32).
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Table 3. Case-fatality rates for Hib and ncHi, by diagnosis and patient age group, Europe, 1996–2006* 
Age group 
Diagnosis <1 mo 1–5 mo 6–11 mo <1 y 1–4 y 5–14 y 15–44 y 45–64 y >65 y NR Total
Hib 
 Meningitis 1/6
(16.7)
3/93
(3.2)
2/98
(2.0)
6/197
(3.0)
11/282
(3.9)
4/45
(8.9)
0/26
(0)
1/17
(5.9)
2/12
(16.7)
0/1
(0)
24/580
(4.1)
 Epiglottitis – 0/1
(0)
0/4
(0)
0/5
(0)
3/110
(2.7)
1/29
(3.4)
2/45
(4.4)
2/37
(5.4)
0/22
(0)
– 8/248
(3.2)
 Cellulitis – 0/7  
(0)
0/18
(0)
0/25
(0)
0/15
(0)
0/3
(0)
– 0/1  
(0)
0/4
(0)
– 0/48  
(0)
 OM/SA – 0/4  
(0)
0/5
(0)
0/9
(0)
0/24
(0)
0/4
(0)
0/4
(0)
0/6
(0)
0/1
(0)
– 0/48  
(0)
 Pneumonia – 0/3  
(0)
0/5
(0)
0/8
(0)
0/20
(0)
0/15
(0)
1/35
(2.9)
1/36
(2.8)
5/47
(10.6)
1/1
(100)
8/162
(4.9)
 Bacteremia 0/11 (0) 2/33
(6.1)
1/30
(3.3)
3/74
(4.1)
6/193
(3.1)
2/73
(2.7)
7/102
(6.9)
4/96
(4.2)
18/134
(13.4)
1/2
(50.0)
41/674
(6.1)
 Other – 1/1
(100.0)
0/2 (0) 1/3
(33.3)
1/10
(10.0)
0/6 (0) 2/10
(20.0)
0/11 (0) 0/7 (0) – 4/47 (8.5)
 NR 0/2 (0) 0/12 (0) 0/8 (0) 0/22 (0) 0/30 (0) 0/21 (0) 1/37
(2.7)
1/37
(2.7)
1/47
(2.1)
0/4 (0) 3/198
(1.5)
 All cases 1/19
(5.3)
6/154
(3.9)
3/170
(1.8)
10/343
(2.9)
21/684
(3.1)
7/196
(3.6)
13/259
(5.0)
9/241
(3.7)
26/274
(9.5)
2/8
(25.0)
88/2,005
(4.4)
ncHi 
 Meningitis 0/8  
(0)
1/15
(6.7)
1/19
(5.3)
2/42
(4.8)
4/76
(5.3)
3/37
(8.1)
0/65
(0)
1/63
(1.6)
2/45
(4.4)
2/4
(50.0)
14/332
(4.2)
 Epiglottitis 1/2
(50.0)
– – 1/2
(50.0)
0/2
(0)
0/1
(0)
0/5
(0)
0/5
(0)
0/3
(0)
– 1/18  
(5.6)
 Cellulitis – – 0/1  
(0)
0/1
(0)
0/4
(0)
0/5
(0)
– – 1/4
(25.0)
– 1/14  
(7.1)
 OM/SA – – – – 0/2  
(0)
0/1
(0)
0/2
(0)
0/2
(0)
0/4
(0)
– 0/11  
(0)
 Pneumonia 3/10
(30.0)
0/14
(0)
1/11
(9.1)
4/35
(11.4)
4/39
(10.3)
2/11
(18.2)
4/34
(11.8)
6/56
(10.7)
40/226
(17.7)
– 60/401
(15.0)
 Bacteremia 22/129
(17.1)
18/53
(34.0)
0/46
(0)
40/228
(17.5)
14/151
(9.3)
2/74
(2.7)
11/236
(4.7)
22/218
(10.1)
131/759
(17.3)
2/10
(20.0)
222/1,676
(13.2)
 Other 2/3
(66.7)
6/8
(75.0)
5/8
(62.5)
13/19
(68.4)
6/21
(28.6)
1/5
(20.0)
0/20
(0)
0/9
(0)
4/38
(10.5)
1/2
(50.0)
25/114
(21.9)
 NR 1/30
(3.3)
5/20
(25.0)
2/13
(15.4)
8/63
(12.7)
3/42
(7.1)
0/19
(0)
1/92
(1.1)
7/111
(6.3)
24/275
(8.7)
0/4
(0)
43/606
(7.1)
 All cases 29/182
(15.9)
30/110
(27.3)
9/98
(9.2)
68/390
(17.4)
31/337
(9.2)
8/153
(5.2)
16/454
(3.5)
36/464
(7.8)
202/135
4 (14.9) 
5/20
(25.0)
366/3,172
(11.5)
*Pediatric cases only for Attiki, Greece (1996–2002); Germany (1998 onward); and Israel (1996 onward). Values are no. deaths/no. cases (case-fatality 
rate). Hib, Haemophilus influenzae type b; ncHi, noncapsulated H. influenzae; OM/SA, osteomyelitis/septic arthritis; NR, not recorded. 
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In contrast to Hif and Hie, invasive Hia infections 
were similar to Hib infection in that they occurred mainly 
in young children who often had meningitis (2). In our 
study, the incidence of Hia in children <5 years of age 
(0.12/million) was much lower than that reported in Na-
vajo and White Mountain Apache children <5 years of age 
(20 cases/100,000 population) (33), Alaska Native chil-
dren <2 years of age (21/100,000) (34), and northern Ca-
nadian aboriginal children <2 years of age (102/100,000) 
(34). The same populations are also highly susceptible 
to invasive Hib disease (35,36). Hia and Hib have the 
most closely related capsules (37) and a similar degree of 
genetic diversity (29).
Infections caused by Hic and Hid are rare and have low 
CFRs, suggesting that they may not be particularly virulent. 
There is a paucity of information on infections caused by 
these serotypes, even in the form of individual case reports. 
Our data suggest that these invasive Hic and Hid infections 
are more common in adults. A recent US study reported 
that, of 770 cases of invasive H. infl uenzae disease during 
1996–2004 in Illinois, 3 (43%) of 7 Hic, and 4 (67%) of 6 
Hid cases occurred in persons 18–64 years of age (28).
That CFR from invasive Hib disease remains low and 
similar to that reported in other industrialized countries is 
reassuring, even though it has not changed substantially 
from the prevaccine era (2,38). In contrast, CFRs for ncHi 
and non–type b encapsulated H. infl uenzae were signifi -
cantly higher than for Hib. The CFRs in our study should 
be considered a minimum because we cannot be sure that 
all deaths would be reported to the surveillance systems, 
particularly if death occurred a considerable time after in-
fection. Other studies with more active follow-up in adults 
with ncHi infections have reported CFRs of 13%–20% (28) 
and up to 29% within 1 month after infection (7). Although 
the high CFRs associated with early-onset neonatal ncHi is 
well described (3), our fi nding of such high CFRs in infants 
was unexpected. Whether these infants had any underly-
ing medical conditions that predisposed them to death or 
the organisms causing infection in this age group are more 
virulent is not known. The CFR for invasive non–type b 
encapsulated H. infl uenzae infections was also higher than 
for Hib and comparable to the 15%–30% reported in other 
studies (7,28). The higher CFR for invasive ncHi infections 
among elderly persons and persons with other clinical di-
agnoses (Table 3) most likely results from a higher preva-
lence of underlying medical conditions predisposing them 
to opportunistic infections. In the latter group, for example, 
ncHi was often isolated from uncommon sterile sites, such 
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Table 4. Epidemiology, diagnosis, and outcome of invasive non–type b Haemophilus influenzae infections, by serotype and age group, 
Europe, 1996–2006* 
Data Hia, n = 26 Hic, n = 9 Hid, n = 12 Hie, n = 143 Hif, n = 500 Total, N = 690 
Diagnosis, no. (%) cases
 Bacteremia 5 (19.2) 1 (11.1) 0 44 (30.8) 157 (31.4) 207 (30.0) 
 Pneumonia 3 (11.5) 3 (33.3) 2 (16.7) 28 (19.6) 91 (18.2) 127 (18.4) 
 Meningitis 6 (23.1) 2 (22.2) 4 (33.3) 22 (15.4) 86 (17.2) 120 (17.4) 
 Other 6 (23.1) 0 (0) 1 (8.3) 30 (21.0) 87 (17.4) 124 (18.0) 
 Unknown 6 (23.1) 3 (33.3) 5 (41.7) 19 (13.3) 79 (15.8) 112 (16.2) 
 Total 26 (100.0) 9 (100.0) 12 (100.0) 143 (100.0) 500 (100.0) 690 (100.0) 
 Median age at disease onset, y (IQR) 2.1
(0.8–43.7) 
52.0
(1.9–53.3) 
36.5
(14.4–47.0) 
65.3
(34.0–8.3) 
61.0
(12.7–75.2) 
60.7
(15.4–75.1) 
Incidence/million cases (total no. cases) by age group, y 
 <5 0.12 (17) 0.02 (3) 0 0.10 (14) 0.78 (106) 1.02 (140) 
 5–64 0.00 (4) 0.00 (5) 0.01 (10) 0.04 (57) 0.12 (171) 0.17 (247) 
>65 0.02 (5) 0.00 (1) 0.01 (2) 0.25 (72) 0.77 (221) 1.04 (301) 
 All age groups 0.01 (26) 0.00 (9) 0.01 (12) 0.08 (143) 0.26 (500)† 0.36 (690)† 
No. cases (%) by age group, y 
 <5 17 (65.4) 3 (33.3) 0 14 (9.8) 106 (21.2) 140 (20.3) 
 5–64 4 (15.4) 5 (55.6) 10 (83.3) 57 (39.9) 171 (34.2) 247 (35.8) 
 >65 5 (19.2) 1 (11.1) 2 (16.7) 72 (50.3) 221 (44.2) 301 (43.6) 
 All age groups 26 (100.0) 9 (100.0) 12 (100.0) 143 (100.0) 500 (100.0)† 690 (100.0)† 
No. (%) deaths by age group, y 
 <5 3 (17.6) 0 – 0 3 (2.8) 6 (4.3) 
 5–64 0 1 (20.0) 0 6 (10.5) 11 (6.4) 18 (7.3) 
 >65 0 0 0 17 (23.6) 22 (10.0) 39 (13.0) 
 All age groups 3 (11.5) 1 (11.1) 0 23 (16.1) 36 (7.2)† 63 (9.1)† 
 Median age at death, y (IQR) 0.50
(0.47–2.3) 
55.0‡ – 70.0
(63.8–88.9) 
72.3
(55.9–83.4) 
70.5
(51.7–83.7) 
*Hia, H. influenzae type a; Hic, H. influenzae type c; Hid, H. influenzae type d; Hie, H. influenzae type e; Hif, H. influenzae type f; IQR, interquartile range. 
†Ages were not known for 2 persons with Hif infection. 
‡Only 1 death was caused by this serotype. 
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as peritoneal and pericardial fl uid, renal and spleen biopsy 
specimens, and brain abscesses, suggesting that such per-
sons may have serious underlying medical conditions at the 
time of infection. Underlying medical conditions also may 
explain why CFRs may be higher for persons with invasive 
Hie infections; the small number of Hie cases compared 
with Hib, ncHi, or Hif suggests that this serotype is not par-
ticularly virulent. Other studies have reported higher CFRs 
for Hie than for Hif, particularly for elderly persons (28).
Thus, despite the reduction in Hib disease, continued 
surveillance is needed for all H. infl uenzae infections across 
all age groups to assess the long-term effectiveness of Hib 
vaccination, rapidly detect unexpected population effects 
and potential changes in circulating strains, and monitor 
changes in the epidemiology of invasive H. infl uenzae dis-
ease. Further studies are needed to defi ne more clearly host 
and pathogen risk factors for invasive H. infl uenzae infec-
tion and factors associated with death.
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